Impact of psychostimulants on vesicular monoamine transporter function

Eur J Pharmacol. 2003 Oct 31;479(1-3):283-9. doi: 10.1016/j.ejphar.2003.08.077.

Abstract

The vesicular monoamine transporter-2 (VMAT-2) facilitates the sequestration of catecholamines and serotonin into synaptic vesicles, and is therefore an essential regulator of monoaminergic neuronal function. VMAT-2 proteins may also play a role in neuroprotection, since these transporters have the capacity to sequester neurotoxins within vesicles. Recent studies have demonstrated that psychostimulants, particularly dopamine "releasers" and "reuptake inhibitors", differentially alter VMAT-2 function. As described in this review, these studies not only provide insight into the pharmacological actions of stimulants, but also mechanisms underlying neurodegenerative disorders, including Parkinson's disease.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Central Nervous System Stimulants / metabolism*
  • Central Nervous System Stimulants / pharmacology
  • Humans
  • Membrane Glycoproteins / agonists
  • Membrane Glycoproteins / antagonists & inhibitors
  • Membrane Glycoproteins / metabolism
  • Membrane Glycoproteins / physiology*
  • Membrane Transport Proteins*
  • Neuropeptides*
  • Vesicular Biogenic Amine Transport Proteins
  • Vesicular Monoamine Transport Proteins

Substances

  • Central Nervous System Stimulants
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Neuropeptides
  • Vesicular Biogenic Amine Transport Proteins
  • Vesicular Monoamine Transport Proteins